Cellumen: Illuminating Cellular Systems Biology
Cellumen, a divison of Apredica, is a Cellular Systems Biology (CSB™) company dedicated to helping researchers create greater numbers of efficacious, safe, and patient-targeted drugs. Our CellCiphr® products and services facilitate the drug discovery and development process by producing better drug candidates more quickly and cost effectively.
Current approaches to discovering, developing, and launching new drugs continue to fall short of the needs of the biopharmaceutical industry and of patients. The approaches that have been used in the last decade have produced only a small pipeline of new drugs, at astronomical costs, as a result of approximately 90% of drug candidates failing in late development. This high failure rate is due primarily to two factors: efficacy and toxicity.
Cellumen is addressing the problems of efficacy and toxicity with the Cellular Systems Biology (CSB™) approach. The CSB™ approach goes beyond the one gene, one target, and one drug paradigm that has driven the biopharmaceutical industry over the last decade. Instead, CSB™ analyzes the systems response of cell lines, primary cells, and patient samples to drug treatments because cells are systems, not merely a collection of parts. By addressing the complexity of cellular system responses we can help you prioritize lead series and improve safety to a significant degree. Our approach has led to the creation of next-generation reagents and multiplexed assays. Our reagents and assays use the High Content Screening (HCS) technology platform but can analyze far more parameters in a systematic way than simple HCS assays. CSB™ is a major step toward a more efficient process for developing safer, more efficacious drugs.
To be the leading provider of proprietary solutions that improve the efficacy and decrease the toxicity of new drug candidates and existing drugs.